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This Perspective discusses the pertinence of variable dosing regimens with anti-
vascular endothelial growth factor (VEGF) for neovascular age-related macular
degeneration (nAMD) with regard to real-life requirements. After the initial pivotal
trials of anti-VEGF therapy, the variable dosing regimens pro re nata (PRN), Treat-and-
Extend, and Observe-and-Plan, a recently introduced regimen, aimed to optimize the
anti-VEGF treatment strategy for nAMD. The PRN regimen showed good visual results
but requires monthly monitoring visits and can therefore be difficult to implement.
Moreover, application of the PRN regimen revealed inferior results in real-life
circumstances due to problems with resource allocation. The Treat-and-Extend
regimen uses an interval based approach and has become widely accepted for its ease
of preplanning and the reduced number of office visits required. The parallel
development of the Observe-and-Plan regimen demonstrated that the future need for
retreatment (interval) could be reliably predicted. Studies investigating the observe-
and-plan regimen also showed that this could be used in individualized fixed
treatment plans, allowing for dramatically reduced clinical burden and good
outcomes, thus meeting the real life requirements. This progressive development of
variable dosing regimens is a response to the real-life circumstances of limited human,
technical, and financial resources. This includes an individualized treatment approach,
optimization of the number of retreatments, a minimal number of monitoring visits,
and ease of planning ahead. The Observe-and-Plan regimen achieves this goal with
good functional results.
Translational Relevance: This perspective reviews the process from the pivotal clinical
trials to the development of treatment regimens which are adjusted to real life
requirements. The article discusses this translational process which– although not the
classical interpretation of translation from fundamental to clinical research, but a
subsequent process after the pivotal clinical trials – represents an important
translational step from the clinical proof of efficacy to optimization in terms of
patients’ and clinics’ needs. The related scientific procedure includes the exploration
of the concept, evaluation of security, and finally proof of efficacy.
Perspective
Major scientific advancements have recently been
made in the management of age-related macular
degeneration (AMD), one of the most frequent
macular pathologies, and AMD has been the focus
of numerous genetic, histologic, pathogenic, ocular
imaging, and therapeutic studies. One of the major
breakthroughs in the management of AMD was the
introduction of antivascular endothelial growth factor
(anti-VEGF) treatment for neovascular AMD
(nAMD). The pivotal trials, the ‘‘Minimally classic/
occult trial of the anti-VEGF antibody ranibizumab
in the treatment of neovascular age-related macular
degeneration’’1 and the ‘‘Anti-VEGF antibody for the
treatment of predominantly classic choroidal neovas-
cularization in age-related macular degeneration’’1
were two multicenter, randomized, controlled, phase
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3 clinical trials in which the efficacy of monthly
intravitreal injections of the anti-VEGF ranibizumab
was shown to significantly improve visual acuity (VA)
compared with sham treatment2 or photodynamic
therapy3 in patients with nAMD. This overwhelming
improvement in the prognosis of nAMD was achieved
on the basis of monthly injections. However, this high
treatment frequency placed a heavy burden on the
management of patients with chronic nAMD, thereby
requiring many clinical and therapeutic interventions
over the course of the patient’s lifespan due to the
repetitive treatment scheme and the inability to
‘‘cure’’ the disease.4 In addition, the incidence of
nAMD is growing, and the increase in life expectancy
is expected to contribute further to this problem.
Soon after the introduction of anti-VEGF treat-
ment for nAMD, alternative retreatment regimens
were explored in order to reduce the treatment
burden. The earliest approach, a fixed reduction to
injections of ranibizumab every 3 months, resulted in
the loss of initial VA improvement and was shown to
be significantly inferior to monthly injections,
although a subset of patients did well on this
regimen.5–7 Several years later, the phase 3 trial
‘‘VEGF trap-eye: investigation of efficacy and safety
in wet AMD’’ (VIEW) with aflibercept, a VEGF
decoy receptor, investigated the outcome of bi-
monthly versus monthly fixed retreatment schedule
and found functional noninferiority at 1 year.8
However, the fluctuating retinal thickness in the
bimonthly regimen suggested that this might be
suboptimal for a significant proportion of eyes.
Thus, any fixed regimen does not appropriately take
into account the high variability of treatment need
between individuals, therefore resulting in overtreat-
ment in patients with low treatment need or
undertreatment in patients with high treatment need.
AMD is a highly variable disorder with a large
spectrum of pathogenic factors, genetic backgrounds,
phenotypic features, and therapeutic responses. Al-
though the reasons are still poorly understood,
patients with nAMD show high interindividual
variability in the need for anti-VEGF injections. This
became evident in the pro re nata (PRN) regimen, the
first individualized treatment regimen.9–12 In this
regimen, the need for retreatment is determined at
monthly assessment visits, allowing for a reduced
number of injections. This individualized regimen was
the first to be widely adopted in clinical practice.
However, monthly monitoring visits are still required
to detect early disease recurrence.
While effective, monthly visits are in reality a
heavy burden on patients and institutions. Indeed,
these monitoring visits are the most time- and
resource-consuming part of patient care with anti-
VEGF therapy for individuals with nAMD. The
number of monitoring visits in turn determines the
requirement for human resources (doctors and
technicians), machines (optical coherence tomogra-
phy [OCT]), and examination space, and these
resources are often limited. In addition to the
institution’s limitations, the patients’ compliance
may be lacking for monthly monitoring visits. A
further downside of the PRN regimen is the constant
uncertainty as to whether a patient will need an
injection, which can cause logistic problems for the
work flow around the injections. Not surprisingly,
recently published real-life data revealed poor func-
tional results,13,14 probably due to general under-
treatment as shown by the low mean number of
injections and the less-than-monthly visits. This may
be a consequence of the aforementioned problems
with logistical issues and limited resources.
These problems have been addressed by the Treat-
and-Extend regimen, which has become the most
commonly used regimen in the United States, and is
becoming increasingly popular internationally. The
cornerstone of the regimen is the progressive length-
ening of the intervals between the visit-injection dates:
Each visit is combined with an injection, and the visit
result determines the subsequent interval to the next
visit-injection date. This approach allowed for reduc-
ing the number of injections and simultaneously the
number of visits. Several reports from 2009 onwards
have shown that overall good VA outcomes may be
achieved with fewer patient visits and injections along
with lower costs compared with fixed, monthly
retreatment.15–17 In comparison with the PRN
regimen, the Treat-and-Extend regimen showed sev-
eral advantages: The number of visits was reduced
along with the number of injections, ranging from 7.6
to 8.4 in the first year.15–17 The injections are
administered at each visit, thereby facilitating the
planning ahead, however, requiring a one-stop clinic
allowing for same day visits and injections. In
addition, several authors have speculated about a
favorable effect of fewer exudative recurrences with
minimized structural damage.
In 2008, during our early experience with PRN,
and before the introduction of the Treat-and-Extend
regimen, our group began to develop a different
treatment algorithm. It started with the clinical
observation of a relatively stable intra-individual
need for retreatment. Based on our experience of
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the challenges of PRN retreatment, we speculated
that it may be possible to combine the advantages of
PRN (minimum number of injections) with the
advantages of a fixed regimen (skipping time-con-
suming visits and planning the injections ahead) if we
could determine the optimal treatment interval for
each individual patient, and if this interval was
relatively stable over time. Thus, we aimed to develop
such a regimen, which would ultimately alleviate the
burden of nAMD care.
In the first step, we performed a pilot study that
investigated the regularity of the individual retreat-
ment need.18 We examined the ability to predict
future need of retreatment on the basis of past
experience with a given individual. In this pilot study,
39 patients agreed to undergo frequent visits. After
the initial three loading doses of ranibizumab every
month, patients were seen at weeks 4, 5, 6, 7, 8, 10, 12,
14, and 16 and then monthly after each injection, until
signs of recurrence were identified on spectral domain
OCT, followed by prompt re-injection. The intensified
visit schedule served to increase the precision of the
recurrence time point. The study duration from
months 3 to 15 allowed for statistical analysis of
intra-individual consecutive treatment intervals of up
to 14 weeks. The results revealed that the intra-
individual standard deviation of the intervals was
limited to 0 to 2 weeks, with the first interval being
predictive of 70% of the variance of the following
intervals.18
On the basis of such regular rhythms and
predictability of retreatment need, our subsequent
study proposed to take advantage of this in a new
regimen, called Observe-and-Plan, and to validate this
regimen by determining its functional outcomes.19
The concept of this regimen was to first measure and
then plan the individual ideal retreatment interval.
This interval is then applied for several fixed
injections without intermittent evaluation. Monitor-
ing visits after each series of injections allow for
adjustment of the interval in the subsequent injection
series. Thus, the advantages of the individualization
(optimal number of injections) and of the fixed
regimen (reduced number of assessment visits and
planning ahead) would be combined. More precisely,
after the initial three loading doses, the patient was
followed in a monthly rhythm until signs of recur-
rence were observed on SD-OCT (i.e., the Observa-
tion period). As this injection-recurrence interval was
considered slightly too long for optimal treatment, the
ideal treatment interval was considered to be 2 weeks
shorter (as there was no sign of recurrence at the
previous month). This was the interval that was
subsequently applied in the individually fixed treat-
ment plan for several injections without monitoring
visit (i.e., the Plan period).19 However, gradual
changes in the need for retreatment may occur over
time. Therefore, readjustment visits were required
after an injection series, with identical intervals from
the last injection, at the latest after 6 months, and/or
after three injections. The interval of the subsequent
treatment plan was adjusted by steps of 2 weeks,
depending on presence or absence of fluid on spectral
domain OCT.19 A dry macula would justify longer
intervals for the next injection series, and fluid on
OCT would prompt shortening of the interval. The
possible treatment plans were: three injections at 1-,
1.5-, or 2-month intervals or two injections at 2.5- or
3-month intervals. Planned treatment intervals longer
than 3 months were not allowed because of the
absence of sufficient data about the stability over
time. When the macula remained dry after a 3-month
interval, the subsequent step was observation every
1.5 to 2 months. Figure 1 shows the sequence of
treatment plans according to the protocol. As an
example, a patient may be monitored monthly after
the initial three loading doses, then show first signs of
recurrence on OCT at 3 months after the last loading
dose. As the macula was dry at 2 months but not at 3
months, the probably best treatment interval was
considered to be 2.5 months. Thus, the patient would
immediately proceed to his fourth injections, followed
by a fifth injection without monitoring visit 2.5
months later. Further 2.5 months later (equivalent
to 5 months¼232.5 months after the last monitoring
visit), the patient would then be clinically assessed
including an OCT, in order to adjust the next
injection intervals to either 2 months (series of three
injections) in case of fluid present on OCT, or extend
to 3 months (series of two injections) in case of a dry
macula, followed by a new assessment visit after a
total of 6 months since the previous assessment visit,
and so on.
The aims of the 2-year study with this Observe-
and-Plan regimen were to validate the regimen based
on functional outcomes and to describe the degree to
which the number of injections and visits could be
reduced.19,20 Although this was not a comparative
study, it was able to show that the Observe-and-Plan
regimen allowed for maintaining the initial visual
benefit over 2 years. While the initial VA improve-
ment is mostly dependent on the tissue potential to
recover function under VEGF suppression, the
retreatment strategy is the main factor for best
TVST j 2015 j Vol. 4 j No. 3 j Article 63
Mantel
possible maintenance of this initial benefit over time.
Thus, the excellent and stable functional results over 2
years using the Observe-and-Plan regimen served as
clinical validation of the regimen.20
Although functional validation of the regimen is
essential, the main interest of the Observe-and-Plan
regimen was to achieve these results with fewer visits
and an individualized number of injections, which are
the main factors impacting the clinical burden: We
found that a mean of four visits after baseline was
needed during the first year, and this was reduced
further to 2.9 visits during the second year. The mean
numbers of injections were 7.8 in the first year
(including loading doses) and 5.8 in the second year,
which were quite similar to other variable-dosing
regimens (Fig. 2).9,12,15,20 However, the number of
visits was three to four times less than what would be
needed in PRN with monthly visits9 and less than half
of what is needed in the Treat-and-Extend regimen
(Fig. 2).15
The main benefit of the Observe-and-Plan regimen
is related to the dramatically lower number of
ophthalmic monitoring visits; because these visits
are the most time- and resource-consuming part of
patient care in individuals with nAMD. The number
of visits determines the institution’s capacity to cope
with the burden of nAMD. Thus, the Observe-and-
Plan regimen enables institutions to care for multiple
patients with nAMD using the same available
resources as compared to PRN or Treat-and-Extend.
Figure 1. Observe-and-Plan regimen with anti-VEGF for neovascular age-related macular degeneration. An overview of the phases
(loading period, observation period, and planned treatment period) and the typical sequence of consecutive treatment plans are shown.
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Second, the regimen offers the ability to plan ahead
for several injections up to 6 months. And third, it is
suitable for both 1-stop and 2-stop clinics: Most of
the injections are planned ahead and predominantly
without an associated visit, which is well compatible
with both types of clinics. Based on these advantages,
this regimen offers an interesting tool to achieve
optimal patient care within the given real-life limita-
tions of restricted resources. In addition, the regimen
may improve patients’ compliance: Patients usually
appreciate not only fewer appointments, less time
spent in clinic, but also the planning ahead for several
months. Hopefully, the increased application of this
Observe-and-Plan regimen will improve the real-life
functional results of anti-VEGF treatment for nAMD
in the future.
The economic impact of the Observe-and-Plan
regimen in terms of direct medical cost is similar to
the PRN and Treat-and-Extend regimen.19 This is not
surprising as the direct medical cost is determined
mainly by the number of injections. However, indirect
cost may be greatly influenced by the number of visits,
as discussed before.
A few challenges of the Observe-and-Plan regimen
should be mentioned. First, as we reported for the
initial 2-year results, late recurrences after more than
3 months of observations may be aggressive and may
sometimes necessitate dramatic shortening of the
treatment interval.20 We therefore recommend careful
evaluation and clinical judgment in cases of late
recurrence. Second, establishing the treatment plan
with several dates and precise intervals requires well-
organized communication and calculation of the
correct timing. This can be greatly facilitated if clinics
can integrate an informatics tool that will calculate
the treatment windows. Third, management of
patients with bilateral nAMD may require some
additional considerations on how to harmonize the
treatment and follow-up dates for the two eyes. In our
experience, the need for retreatment is often amaz-
ingly parallel. If not, it is helpful to slightly modify the
by-protocol intervals. Minor interval adjustments or
application of a slightly different number of retreat-
ments may help to establish a harmonized treatment
for both eyes (for example 4 3 1.25 and 2 3 2.5
months). It is usually possible to find a solution in
which one eye receives injections every second or third
time that the other eye is injected. Thus, the benefit of
the regimen can be maintained, even in patients with
bilateral nAMD.
In conclusion, the development of the Observe-
and-Plan regimen illustrates a scientific process
subsequent to the phase 3 clinical trials. During this
process, the efficacy target set by the clinical trials was
translated into a treatment approach that takes into
account real-life requirements and challenges. In
comparison with the initially proposed fixed monthly
regimen of anti-VEGF injections for nAMD, the
Figure 2. Comparison of injection and visit numbers for different retreatment regimens.
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earliest variable-dosing regimen (PRN), which re-
duced the number of injections, and the subsequent
introduction of the Treat-and-Extend regimen yielded
a better planning-ahead protocol and reduced the
number of visits. Finally, the Observe-and-Plan
regimen was able to achieve good functional out-
comes with dramatically reduced numbers of visits
and a number of injections, as required by the
pathology of the individual patient. This was obtained
by individualized prediction of the need for retreat-
ment. Because fewer visits are needed, and due to the
additional advantage of the ease of preplanning of the
injections, the development of this regimen enabled
the optimization of human and technical resources.
The Observe-and-Plan regimen can alleviate the
clinical burden of anti-VEGF treatment for patients
with nAMD, thereby improving the institutional
capacity for chronic care management of this
disorder.
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